$0.117
-0.010 (-8.44%)Al cierre
- High
- 0.121
- Open
- 0.115
- VWAP
- 0.11
- Vol
- 14.99M
- Mkt Cap
- 153.15M
- Low
- 0.103
- Amount
- 1.71M
- EV/EBITDA, TTM
- 0.00
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. Its lead product candidates include Tamibarotene and SY-2101. Its Tamibarotene, is a selective retinoic acid receptor alpha (RARα), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). The Company’s product candidate also includes SY-5609, which is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being developed for patients with select solid tumors and in combination with gemcitabine and with gemcitabine plus nab-paclitaxel in patients with metastatic pancreatic cancer. It is also focused on the development for the treatment of multiple preclinical programs in oncology.
Analyst Ratings (7)
Brookline Capital
—
2024-11-13
Brookline Capital
2024-11-13
Precio objetivo
—
JMP Securities
—
2024-11-13
JMP Securities
2024-11-13
Precio objetivo
—
HC Wainwright & Co.
$1
2024-11-13
HC Wainwright & Co.
2024-11-13
Precio objetivo
$1
TD Cowen
—
2024-11-13
TD Cowen
2024-11-13
Precio objetivo
—
HC Wainwright & Co.
$6
2024-11-01
HC Wainwright & Co.
2024-11-01
Precio objetivo
$6
Métricas de valoración
Cronología de eventos
Noticias
8.504-15SeekingAlphaRege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals
8.504-15NewsfilterRege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials
4.503-18BenzingaDow Dips Over 200 Points; US Industrial Production Increases More than Expected
4.503-11BenzingaUS Stocks Mixed; Kohl's Shares Plunge After Q4 Results
9.003-07Business InsiderBiotech Alert: Searches spiking for these stocks today
SYRS FAQ — answered by Alphio AI
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. Its lead product candidates include Tamibarotene and SY-2101. Its Tamibarotene, is a selective retinoic acid receptor alpha (RARα), agonist RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). Its SY-2101, is an oral form of arsenic trioxide (ATO) being developed for the treatment of acute promyelocytic leukemia (APL). The Company’s product candidate also includes SY-5609, which is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) which is being developed for patients with select solid tumors and in combination with gemcitabine and with gemcitabine plus nab-paclitaxel in patients with metastatic pancreatic cancer. It is also focused on the development for the treatment of multiple preclinical programs in oncology. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
7 analysts cover SYRS: 5 rate it Buy, 2 Hold and 0 Sell.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.